NCT07933536
A Study to Assess Targeted Therapies for Treatment of Adults With Moderate to Severe Psoriasis
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Percentage of Participants Achieving at least a 90% reduction from Baseline in Psoriasis Area and Severity Index (PASI 90)
Timeframe: Week 28
Number of Participants with Adverse Events (AEs)
Timeframe: Up to 72 Weeks
Secondary (3)
Percentage of Participants Achieving 100% Reduction from Baseline in PASI 100
Percentage of Participants Achieving ≥10% Body Weight Reduction from Baseline
Percent Change from Baseline in Body Weight
Arms and interventions
Risankizumab and ABBV-295 Combination TherapyExperimental
Participants will receive risankizumab in combinations with ABBV-295 for up to 52 weeks.
Risankizumab and ABBV-295 Matching PlaceboActive comparator
Participants will receive risankizumab with ABBV-295 matching placebo for up to 52 weeks.
Drugs: Risankizumab, ABBV-295, ABBV-295 Placebo